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Introduction
IL-1b, an inflammatory cytokine, plays an important role
in SJIA, a rare autoinflammatory disease. Canakinumab
(CAN), a selective fully human, anti-IL-1b monoclonal
antibody, is reported to be efficacious in treating SJIA.
Objectives
To characterize changes in peripheral blood gene expres-
sion and inflammatory proteins in SJIA patients (pts)
treated with CAN and to identify baseline biomarkers
that predict clinical response to CAN treatment.
Methods
Levels of inflammatory biomarkers (IL6; total IL18) and
gene expression profiles of active SJIA pts (aged 2-19 yrs)




Transcriptional changes upon CAN treatment at Day 3
were assessed. When applying cut-offs of ≥2 fold and
p ≤ 0.05, no transcript passed this filter for placebo pts
and for CAN pts that were ACR30 (adapted pediatric
ACR) non-responders at Day 15, while 171 probesets
passed the filter for pts showing ≥ACR30 response. Pts
who showed strong transcriptional changes also showed
a strong ACR response (≥ACR50) at Day 15, while pts
with <ACR50 at Day 15 showed a much weaker tran-
scriptional response at Day 3. Strongly repressed genes
included many known inflammation and innate immu-
nity-related genes (eg, TLR1, TLR4, TLR5, TLR6,
TLR8), including several members of the IL-1b signaling
pathway, such as IL1b, IL1R1, IL1R2 and IL1RAP. A set of
transcripts was identified for which high baseline expres-
sion levels predicted a subgroup of strong (≥ACR50)
responders at Day 15. However, another subgroup of
strong responders was indistinguishable from weak
responders (≤ACR30) based on baseline transcript levels.
Protein markers
IL-6 protein levels were strongly reduced by Day 3 (4.7×
and 4.4× with p = 0.002 and 0.0001, for the 2 trials), and
at Day 29 (12.5 × and 8.1 × with p = 0.01 and 0.00005,)
while total IL18 levels remained largely unchanged until
Day 29 and showed a moderate reduction only at Day 57.
For IL6, stronger reduction at Day 3 and Day 29 was
observed for pts who showed stronger ACR response at
Day 15. Only 3 baseline samples were available from pts
who developed macrophage activation syndrome during
the studies.
Conclusion
CAN treatment resulted in a rapid, strong reduction of
many pro-inflammatory leukocyte transcripts and serum
IL6. Compared with IL6, IL18 protein levels were reduced1NIBR, MA, USA
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upon treatment much later and less strongly. About two
thirds of pts with a strong treatment response (≥ACR50)
were characterized by a set of leukocyte transcripts with
high baseline levels and strong reduction upon CAN treat-
ment. However, the remaining one third of CAN strong
responders did not show these characteristic transcrip-
tional patterns, suggesting some heterogeneity at the
molecular level in SJIA pts showing strong response to
CAN treatment.
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